Dr. Tripathy Discusses the MONALEESA-7 Trial in HR+ Breast Cancer

June 2, 2019
Debu Tripathy, MD,

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the MONALEESA-7 trial in hormone receptor-positive breast cancer.

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the MONALEESA-7 trial in hormone receptor-positive breast cancer.

Over the last few years, CDK4/6 inhibitors have impacted clinical practice due to their ability to double progression-free survival. Thus far, of all of the 3 CDK4/6 inhibitors that are approved by the FDA, the trials had PFS as their primary endpoint. However, an overall survival analysis (OS) was integrated into these studies. MONALEESA-7 is the first of these trials to have reached that landmark and show a survival benefit, Tripathy explains.

The updated data of the phase III trial showed that treatment with ribociclib (Kisqali) and endocrine therapy demonstrated a statistically significant improvement in OS compared with placebo/endocrine therapy in this patient population, Tripathy concludes.

<<< 2019 ASCO Annual Meeting

x